April 18, 2014
Astellas Pharma and MSD K.K. announced on April 17 the launch of Japan’s first selective sodium-glucose co-transporter-2 (SGLT-2) inhibitor Suglat Tablets 25 mg and 50 mg (ipragliflozin L-proline) for the treatment of type 2 diabetes. Its NHI price is 136.50...read more